isradipine has been researched along with Disease Models, Animal in 25 studies
Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The L-type calcium channel blocker isradipine was devoid of neuroprotective activity in focal and global models of cerebral ischemia in three species of normotensive animals." | 7.69 | Failure of isradipine to reduce infarct size in mouse, gerbil, and rat models of cerebral ischemia. ( Bailey, SJ; Hamilton, TC; Harrison, DC; Hunter, AJ; King, PD; Roberts, JC; Rothaul, AL; Samson, NA; Wood, NI, 1995) |
| "The L-type calcium channel blocker isradipine was devoid of neuroprotective activity in focal and global models of cerebral ischemia in three species of normotensive animals." | 3.69 | Failure of isradipine to reduce infarct size in mouse, gerbil, and rat models of cerebral ischemia. ( Bailey, SJ; Hamilton, TC; Harrison, DC; Hunter, AJ; King, PD; Roberts, JC; Rothaul, AL; Samson, NA; Wood, NI, 1995) |
| "The effect of regression of left ventricular hypertrophy was studied in deoxycorticosterone-acetate-salt hypertensive rats (DOCA-salt hypertensive rats) treated with tetrandrine." | 3.69 | Effects of tetrandrine on left ventricle hypertrophy in deoxycorticosterone acetate-salt hypertensive rats. ( Rao, MR; Xu, Y, 1995) |
| "We report the effects of two new dihydropyridine derivatives, isradipine (4-(4'-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedic arboxylic acid methylisopropylester) and niguldipine (1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinecarboxylic acid 3-(4,4-diphenyl-1-piperidinyl)-propyl methyl ester hydrochloride), and of dantrolene (1-[(5-[p-nitrophenyl]furfurylidene)-amino]hydantoin sodium, an inhibitor of Ca2+ release from intracellular stores) on the protective efficacy of antiepileptic drugs against maximal electroshock-induced seizures." | 3.69 | Influence of isradipine, niguldipine and dantrolene on the anticonvulsive action of conventional antiepileptics in mice. ( Borowicz, KK; Czuczwar, SJ; Gasior, M; Kleinrok, Z, 1997) |
| " Nevertheless, experiments in atherosclerotic animals indicate that the dose has to be chosen more cautiously than for young animals, as the dose-response curve for several effects is bell-shaped." | 2.38 | Calcium antagonists in experimental atherosclerosis. Use-dependence of isradipine: a potential explanation for enhanced action in atherosclerotic animals and tissue selectivity. ( Hof, RP; Rüegg, UT, 1991) |
| "Isradipine has proved to be the most potent and effective calcium antagonist for reducing the infarct size compared with other representatives of this class of drugs such as nimodipine, nicardipine and flunarizine." | 2.38 | Experimental studies with isradipine in stroke. ( Rudin, M; Sauter, A, 1990) |
| "Treatment with isradipine prevented against MPP+-induced iron influx in the MES23." | 1.46 | Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice. ( Liu, S; Ma, ZG; Wang, QM; Xu, YY, 2017) |
| "Parkinson's disease is a common, debilitating, neurodegenerative disorder for which the current gold standard treatment, levodopa (L-DOPA) is symptomatic." | 1.46 | Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson's Disease. ( Cronin, A; Grealy, M, 2017) |
| "Isradipine-treated animals displayed a dose-dependent reduction in L-DOPA-induced rotational behavior and abnormal involuntary movements." | 1.35 | Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. ( Aubert, I; Berthet, A; Bezard, E; Bloch, B; Cenci, MA; Doudnikoff, E; Hengerer, B; Ittrich, C; Rylander, D; Schuster, S; Surmeier, DJ, 2009) |
| " Practically identical isradipine dose-response neuroprotection curves were observed for both measurement procedures." | 1.35 | Brain MRI and neurological deficit measurements in focal stroke: rapid throughput validated with isradipine. ( Barone, FC; Chandra, S; Lenhard, SC; Price, WJ; Strittmatter, R; White, RF, 2008) |
| " An initial dose-response study using neurological deficit scores and estimates of protection from brain infarction (by histology) showed that isradipine reduced cortical infarctions compared to vehicle-treated animals at most doses (between 1." | 1.30 | Use of diffusion-weighted MRI and neurological deficit scores to demonstrate beneficial effects of isradipine in a rat model of focal ischemia. ( Barone, FC; Chandra, S; Coatney, RW; Everding, D; Feuerstein, GZ; Sarkar, SK; White, RF, 1999) |
| "When isradipine was given either during cholesterol feeding and continued for four weeks following it (subgroup 5) or during the four weeks following cholesterol feeding (subgroup 6), loss of endothelium dependent relaxation and the accumulation of cholesterol in the aorta was prevented." | 1.29 | Effect of isradipine on the formation and regression of fatty streaks in cholesterol fed rabbits. ( Kappagoda, CT; Kunjara-Na-Ayudhya, R; Thomson, AB, 1994) |
| " Dose-response curves reveal that isradipine is one of the most potent and efficacious representatives of this class of compounds, reducing the infarct size by more than 60%." | 1.28 | Prevention of stroke and brain damage with calcium antagonists in animals. ( Rudin, M; Sauter, A, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (44.00) | 18.2507 |
| 2000's | 6 (24.00) | 29.6817 |
| 2010's | 5 (20.00) | 24.3611 |
| 2020's | 3 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Wickline, JL | 1 |
| Smith, S | 1 |
| Shin, R | 1 |
| Odfalk, K | 1 |
| Sanchez, J | 1 |
| Javors, M | 1 |
| Ginsburg, B | 1 |
| Hopp, SC | 1 |
| Vaz, RL | 1 |
| Sousa, S | 1 |
| Chapela, D | 1 |
| van der Linde, HC | 1 |
| Willemsen, R | 1 |
| Correia, AD | 1 |
| Outeiro, TF | 1 |
| Afonso, ND | 1 |
| Wang, QM | 1 |
| Xu, YY | 1 |
| Liu, S | 1 |
| Ma, ZG | 1 |
| Cronin, A | 1 |
| Grealy, M | 1 |
| Schuster, S | 1 |
| Doudnikoff, E | 1 |
| Rylander, D | 1 |
| Berthet, A | 1 |
| Aubert, I | 1 |
| Ittrich, C | 1 |
| Bloch, B | 1 |
| Cenci, MA | 1 |
| Surmeier, DJ | 3 |
| Hengerer, B | 1 |
| Bezard, E | 1 |
| Chan, CS | 1 |
| Gertler, TS | 1 |
| Ilijic, E | 1 |
| Guzman, JN | 1 |
| Copenhaver, PF | 1 |
| Anekonda, TS | 1 |
| Musashe, D | 1 |
| Robinson, KM | 1 |
| Ramaker, JM | 1 |
| Swanson, TL | 1 |
| Wadsworth, TL | 1 |
| Kretzschmar, D | 1 |
| Woltjer, RL | 1 |
| Quinn, JF | 1 |
| Verbois, SL | 1 |
| Scheff, SW | 1 |
| Pauly, JR | 1 |
| Kaya Dağistanli, F | 1 |
| Süsleyici Duman, B | 1 |
| Oztürk, M | 1 |
| Lenhard, SC | 1 |
| Strittmatter, R | 1 |
| Price, WJ | 1 |
| Chandra, S | 2 |
| White, RF | 2 |
| Barone, FC | 2 |
| Bailey, SJ | 1 |
| Wood, NI | 1 |
| Samson, NA | 1 |
| Rothaul, AL | 1 |
| Roberts, JC | 1 |
| King, PD | 1 |
| Hamilton, TC | 1 |
| Harrison, DC | 1 |
| Hunter, AJ | 1 |
| Xu, Y | 1 |
| Rao, MR | 1 |
| Ikeda, S | 1 |
| Amano, Y | 1 |
| Adachi-Akahane, S | 1 |
| Nagao, T | 1 |
| Kunjara-Na-Ayudhya, R | 1 |
| Thomson, AB | 1 |
| Kappagoda, CT | 1 |
| Gruver, EJ | 1 |
| Glass, MG | 1 |
| Marsh, JD | 1 |
| Gwathmey, JK | 1 |
| Sauter, A | 3 |
| Rudin, M | 3 |
| Borowicz, KK | 1 |
| Gasior, M | 1 |
| Kleinrok, Z | 1 |
| Czuczwar, SJ | 1 |
| Everding, D | 1 |
| Feuerstein, GZ | 1 |
| Coatney, RW | 1 |
| Sarkar, SK | 1 |
| Zavecz, JH | 1 |
| Bueno, O | 1 |
| Maloney, RE | 1 |
| O'Donnell, JM | 1 |
| Roerig, SC | 1 |
| Battarbee, HD | 1 |
| Milnes, JT | 1 |
| MacLeod, KT | 1 |
| Hof, RP | 1 |
| Rüegg, UT | 1 |
2 reviews available for isradipine and Disease Models, Animal
| Article | Year |
|---|---|
Calcium antagonists in experimental atherosclerosis. Use-dependence of isradipine: a potential explanation for enhanced action in atherosclerotic animals and tissue selectivity.
Topics: Animals; Arteriosclerosis; Calcium Channel Blockers; Cardiovascular System; Disease Models, Animal; | 1991 |
Experimental studies with isradipine in stroke.
Topics: Animals; Antihypertensive Agents; Cerebrovascular Circulation; Cerebrovascular Disorders; Disease Mo | 1990 |
23 other studies available for isradipine and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
L-type calcium channel antagonist isradipine age-dependently decreases plaque associated dystrophic neurites in 5XFAD mouse model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Calcium Channel B | 2023 |
Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopaminergic Ne | 2020 |
Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Calcium Channel Blockers; Calcium | 2017 |
Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson's Disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Disease Models, Animal; Dopaminergic Neurons; Drug | 2017 |
Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cerebrum; Dendritic Spines; Disease Mod | 2009 |
A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease.
Topics: Aging; Animals; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Disease Models, Animal; | 2010 |
The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Dihydropyridines; Disease Models, Anima | 2011 |
A translational continuum of model systems for evaluating treatment strategies in Alzheimer's disease: isradipine as a candidate drug.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Biological Assay; Calcium Channels, L-Type; Cell | 2011 |
Chronic nicotine treatment attenuates alpha 7 nicotinic receptor deficits following traumatic brain injury.
Topics: Animals; Autoradiography; Binding, Competitive; Brain; Brain Injuries; Bridged Bicyclo Compounds, He | 2003 |
Protective effects of a calcium channel blocker on apoptosis in thymus of neonatal STZ-diabetic rats.
Topics: Animals; Animals, Newborn; Apoptosis; Blood Glucose; Calcium Channel Blockers; Cell Count; Dexametha | 2005 |
Brain MRI and neurological deficit measurements in focal stroke: rapid throughput validated with isradipine.
Topics: Animals; Behavior, Animal; Brain Infarction; Calcium Channel Blockers; Disease Models, Animal; Israd | 2008 |
Failure of isradipine to reduce infarct size in mouse, gerbil, and rat models of cerebral ischemia.
Topics: Animals; Brain Ischemia; Calcium Channel Blockers; Cerebral Infarction; Disease Models, Animal; Gerb | 1995 |
Effects of tetrandrine on left ventricle hypertrophy in deoxycorticosterone acetate-salt hypertensive rats.
Topics: Alkaloids; Animals; Antihypertensive Agents; Benzylisoquinolines; Binding, Competitive; Blood Pressu | 1995 |
Binding of [3H](+)-PN200-110 to aortic membranes from normotensive and spontaneously hypertensive rats.
Topics: Aging; Animals; Aorta, Abdominal; Aorta, Thoracic; Calcium Channels; Disease Models, Animal; Hyperte | 1994 |
Effect of isradipine on the formation and regression of fatty streaks in cholesterol fed rabbits.
Topics: Acetylcholine; Animals; Aorta; Arteriosclerosis; Cholesterol, Dietary; Disease Models, Animal; Dose- | 1994 |
An animal model of dilated cardiomyopathy: characterization of dihydropyridine receptors and contractile performance.
Topics: Analysis of Variance; Animals; Calcium Channels; Calcium Channels, L-Type; Cardiomyopathy, Dilated; | 1993 |
Failure of isradipine in cerebral ischemia models.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Gerbillinae; Isradipine; Mice; | 1996 |
Influence of isradipine, niguldipine and dantrolene on the anticonvulsive action of conventional antiepileptics in mice.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1997 |
Use of diffusion-weighted MRI and neurological deficit scores to demonstrate beneficial effects of isradipine in a rat model of focal ischemia.
Topics: Animals; Brain Ischemia; Calcium Channel Blockers; Disease Models, Animal; Dose-Response Relationshi | 1999 |
Cardiac excitation-contraction coupling in the portal hypertensive rat.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2000 |
Reduced ryanodine receptor to dihydropyridine receptor ratio may underlie slowed contraction in a rabbit model of left ventricular cardiac hypertrophy.
Topics: Animals; Antihypertensive Agents; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Cells | 2001 |
Prevention of stroke and brain damage with calcium antagonists in animals.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Brain Damage, Chronic; Calcium Channel Blockers; C | 1991 |